SBIR Phase I: Bioactive, High-Strength Contrast Agents for Orthopedic and Bone Applications

SBIR 第一阶段：用于骨科和骨科应用的生物活性高强度造影剂

• 批准号: 1247933
• 负责人: Joseph Bringley
• 金额: $ 15万
• 依托单位: TRANSPARENT MATERIALS, LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-01-01 至 2013-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1247933&HistoricalAwards=false
• 关键词: SBIR; Phase; Bioactive; Strength; Contrast

This Small Business Innovation Research (SBIR) Phase I project seeks to develop bioactive, high-strength contrast agents for use in orthopedic and bone implant applications. There is a clear clinical need for improved contrast agents that increase the strength, toughness and abrasion wear of bone-void fillers, improve its biocompatibility and ability to promote the growth of healthy bone at the bone/filler interface. The innovation addresses the current shortcomings and aims to produce contrast agents that improve the mechanical properties, fatigue life, wear abrasion, and bio-compatibility with living bone. The broader impact/commercial potential of this project is to increase the success rate of total joint replacement surgeries, increase the implant lifetime and reduce the rates of revision surgeries. Surgeries involving hip and knee replacements (and other surgeries utilizing bone-void fillers) are rapidly increasing world-wide, and the trend toward performing these surgeries on a younger patient population, who will more likely require replacement surgeries, portends a massive increase in their incidence in the coming decades.

该小型企业创新研究（SBIR）第一阶段项目旨在开发用于骨科和骨植入应用的生物活性高强度造影剂。临床上明显需要改进的造影剂，以增加骨空隙填充物的强度、韧性和磨损，改善其生物相容性和促进骨/填充物界面处健康骨生长的能力。该创新解决了当前的缺点，旨在生产改善机械性能、疲劳寿命、磨损和与活骨的生物相容性的造影剂。 该项目更广泛的影响/商业潜力是提高全关节置换手术的成功率，延长植入物寿命并降低翻修手术率。涉及髋关节和膝关节置换的外科手术（以及其他利用骨空隙填充物的手术）在全球范围内迅速增加，并且在更年轻的患者人群中进行这些手术的趋势，这些患者更可能需要置换手术，预示着未来几十年其发病率将大幅增加。